GUJARAT KIDNEY & SUPER SPECIALITY IPO
Dhan Kirti is pleased to bring you a comprehensive overview of the upcoming Initial Public Offering (IPO) of Gujarat Kidney & Super Speciality Limited. This IPO presents an opportunity for investors to participate in a growing regional healthcare provider in Gujarat. As the healthcare sector continues to evolve, understanding the nuances of such offerings is crucial for informed investment decisions. This blog post delves into the IPO details, company background, financial objectives, and key considerations for potential investors.
Key IPO Details at a Glance
| IPO Period | 22nd – 24th Dec 2025 |
|---|---|
| Listing on | 30 Dec 2025 |
| Price Band | ₹108 – ₹114 per equity share |
| Lot Size & Minimum Investment | 128 shares – ₹14,592 |
| Total Issue Size | ₹250.80 Crores |
Gujarat Kidney & Super Speciality IPO is a book-built issue, entirely a fresh issue of equity shares. This means all proceeds from the IPO will go directly to the company, aiding its growth and expansion initiatives. The company aims to leverage this capital to strengthen its healthcare infrastructure and service offerings.
Important Dates for Investors
Understanding the IPO timeline is essential for all prospective investors to ensure timely application and tracking of their investment.
- Opening Date: 22 Dec 2025
- Closing Date: 24 Dec 2025
- UPI Payment Deadline: 24 Dec 2025 (5 PM)
- Allotment Announcement: 26 Dec 2025
- Refund Processing: 29 Dec 2025
- Demat Credit: 29 Dec 2025
- Stock Market Listing: 30 Dec 2025
- Mandate Validity End: 09 Jan 2026
- Anchor Investor Lock-in Release (50%): 25 Jan 2026
- Anchor Investor Lock-in Release (Remaining): 26 Mar 2026
*Dates may be revised as per official updates. Investors are advised to refer to official exchange notifications for the most current schedule.
Exploring Gujarat Kidney & Super Speciality Limited
Founded in 2019 and later renamed to reflect its expanded clinical focus, Gujarat Kidney and Super Speciality Limited operates as a prominent regional healthcare provider. The company manages a network of mid-sized multi-speciality hospitals across central Gujarat, delivering integrated secondary and tertiary care services. Its operations are concentrated in key locations such as Vadodara, Godhra, Bharuch, Borsad, and Anand.
The company’s service portfolio is comprehensive, encompassing inpatient and outpatient care, advanced diagnostics, surgical and critical care, and in-house pharmacy operations. Gujarat Kidney & Super Speciality currently operates seven hospitals and four in-house pharmacies, boasting a total bed capacity of 490 (with 445 approved and 340 operational beds). The business model strategically combines owned and acquired facilities, allowing for scalable expansion and efficient integration of new healthcare units.
Promoted by experienced medical and managerial professionals including Dr Pragnesh Yashwantsinh Bharpoda, Dr Bhartiben Pragnesh Bharpoda, Dr Yashwantsinh Motisinh Bharpoda, and Anitaben Yashwantsinh Bharpoda, the company is well-positioned to address the increasing healthcare demands in Gujarat’s semi-urban and urban areas. Its commitment to technology adoption and speciality-driven services further strengthens its regional footprint.
IPO Structure and Capital Generation
The Gujarat Kidney & Super Speciality IPO is structured entirely as a fresh issue, ensuring that all capital raised directly contributes to the company’s growth initiatives. This approach typically signifies a company’s intent to fund future expansion and operational enhancements.
| Total Funds Raised | ₹250.80 Crores |
|---|---|
| Fresh Issue Component | ₹250.80 Crores |
| Offer for Sale Component | Not Applicable |
Since the entire issue is a fresh issue, the company will receive all the proceeds, which will be strategically deployed for its stated objectives, including acquisitions, capital expenditure, and debt reduction. This capital infusion is expected to bolster the company’s financial strength and support its ambitious growth trajectory within the healthcare sector.
Deployment of IPO Proceeds
Gujarat Kidney & Super Speciality Limited plans to utilize the funds raised from the IPO for several strategic initiatives aimed at expanding its network, upgrading facilities, and enhancing operational capabilities. A significant portion is allocated towards both organic and inorganic growth.
| Objective | Amount (INR Crores) | Allocation % |
|---|---|---|
| Acquisition of Parekhs Hospital, Ahmedabad | 77.00 | 30.70% |
| Part-payment for Ashwini Medical Centre | 12.40 | 4.94% |
| Capital expenditure for a new hospital in Vadodara | 30.10 | 12.00% |
| Robotics equipment at Vadodara hospital | 6.83 | 2.72% |
| Repayment/prepayment of secured borrowings | 1.20 | 0.48% |
| Acquisition of additional stake in Harmony Medicare (Bharuch) | 10.78 | 4.30% |
| General corporate purposes | 112.49 | 44.86% |
The planned use of capital demonstrates a clear strategy for expansion and technological advancement. Acquisitions like Parekhs Hospital and increased stake in Harmony Medicare signify inorganic growth, while capital expenditure for new facilities and advanced equipment like robotics show a commitment to organic development and enhanced service delivery. The allocation for general corporate purposes provides flexibility for future strategic needs and operational efficiencies.
Distinctive Strengths of the Company
Gujarat Kidney & Super Speciality Limited possesses several key strengths that contribute to its competitive positioning and potential for sustained growth in the healthcare industry:
- Strong capabilities in renal sciences with established urology subspecialties: This specialization allows the company to cater to a critical and high-demand medical area, establishing a strong reputation and patient base for kidney-related treatments and surgeries.
- Strategically located, right-sized hospitals providing efficient capital returns: The hospitals are positioned in areas of high demand within central Gujarat, and their optimized size ensures operational efficiency and potentially higher returns on invested capital.
- Proven ability to attract, train, and retain skilled medical professionals: A strong team of doctors and healthcare staff is fundamental to healthcare quality. The company’s ability to maintain a skilled workforce ensures high standards of patient care and operational stability.
- Continuous investment in infrastructure and clinical processes supporting affordable care: By regularly upgrading its facilities and refining clinical protocols, the company aims to provide modern healthcare services while maintaining affordability, catering to a broader patient demographic.
- Strong operational and financial performance with a track record of growth: A consistent track record of operational efficiency and financial growth signals stability and effective management, which can instill confidence in investors regarding future prospects.
Key Considerations and Risk Factors
While the company exhibits strong growth potential, investors should also be aware of certain inherent risks associated with its operations and the healthcare sector:
- The company has acquired several hospitals from promoters and may continue such related-party acquisitions: While these acquisitions can facilitate growth, related-party transactions require careful scrutiny to ensure they are at arm’s length and in the best interest of all shareholders.
- Acquisitions and integrations involve operational, financial, and regulatory risks: Expanding through acquisitions can bring challenges related to blending different organizational cultures, integrating IT systems, managing finances across new entities, and navigating diverse regulatory frameworks.
- Rapid expansion across multiple hospitals increases management and operational complexity: Scaling operations quickly can strain management resources and introduce complexities in maintaining consistent service quality and operational standards across all facilities.
- Dependence on promoter-led expertise poses concentration and continuity risks: A high reliance on the specialized knowledge and leadership of promoters, while currently a strength, could become a risk if key individuals depart or if succession planning is not robust.
- Hospitals lacking certain departments may limit service breadth: While specialized in renal care, a lack of certain departments in some hospitals might restrict the comprehensive range of services offered, potentially affecting patient inflows or necessitating referrals to other facilities.
Live Subscription Performance
Subscription data offers insights into investor interest across various categories. As of the latest available information, the IPO has garnered varying levels of interest from different investor segments.
Subscription statistics based on the latest available information as of 05:00 PM on December 22, 2025:
| Investor Category | Shares Reserved (Lakhs) | Shares Applied (Lakhs) | Subscription (Times) |
|---|---|---|---|
| Qualified Institutional Buyers (QIB) | 77.27 | 26.41 | 0.34 |
| Non-Institutional Investors (NII) | 33.00 | 64.86 | 1.97 |
| Retail Individual Investors (RII) | 22.00 | 103.46 | 4.70 |
| Total | 132.27 | 194.73 | 1.47 |
*Please note that subscription figures are dynamic and may change throughout the IPO period. Exchange data is considered the most reliable indicator of investor interest. Information regarding Grey Market Premium (GMP) is unofficial and speculative; investors should rely on official subscription data.
Participating in the IPO
Investing in an IPO can be a strategic move for portfolio diversification, especially in high-growth sectors like healthcare. Gujarat Kidney & Super Speciality Limited’s IPO offers an opportunity to invest in a company with a focused growth strategy and a strong regional presence.
Investors can participate in this IPO via the official Dhan Kirti IPO platform before the subscription closes. We encourage all prospective investors to conduct their due diligence and consult with a financial advisor to align their investment decisions with their financial goals and risk appetite.
